Ardea Biosciences, Inc. (NASDAQ:RDEA)
| CAPS Rating |
|
|---|---|
| Open | $18.82 |
| Previous Close | $19.00 |
| Daily Range | $18.52 - $18.96 |
| 52-Week Range | $13.15 - $29.58 |
| Market Cap | $502.96M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 102,049 |
| Average Daily Volume | 0 |
RDEA
VS S&P 500 (SPY)
How do you think RDEA will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
RDEA Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
RDEA News and Commentary
- Gout Drug Developer BioCryst Rises on Study – Minyanville
- Rebound Ideas: Top 6 Oversold Stocks With Insider Buying – The Motley Fool
- Investing 101: The Top 10 Losers That Have Seen Insider Buying – The Motley Fool
- Three Biotech Stocks on the Edge of Success – SeekingAlpha
- 3 Biotech Stocks on the Edge of Success – SeekingAlpha
- Analyst Calls: DAL, CIEN, DGX, HD, IMAX, LOW, OSK, PENN, RDS.A, SWK ... – BloggingStocks
- Stocks With the Most and the Best Analyst Ratings – SeekingAlpha
- Top 15 Most Undervalued Rally Stocks – SeekingAlpha
- Life Science Portfolios: Reflecting on a Year of Out-Performance – SeekingAlpha
- 11 Rebounding Stocks With Bullish Options Sentiment – SeekingAlpha
- 16 Stocks Ready For A Short Squeeze – Blog at The Motley Fool
- 'New Market Wizards': Lessons From Stanley Drukenmiller – SeekingAlpha
- The Daily Long & Short Setup – Blog at The Motley Fool
- UPDATE 1-Ardea says gout drug meets mid-stage study goal – Reuters
- The Next Million-Dollar Penny Stock – The Motley Fool
- Health Care Stocks Need Quite A Surge To Meet Latest Analyst Targets – SmartMoney
- Ardea Takes the More Exciting Route – The Motley Fool
Related News and Articles
- The Skinny on Upcoming Obesity FDA Meetings – The Motley Fool
RSS Headlines
Fool UK
